- 1962
- Launched Japan’s first reagent for serum transaminase (GOT, GPT) measurement
- 1982
- Launched LPIA 1
- 1987
- Launched LPIA 100
- 1989
- “Enzyme-Electrode Method” transferred from MEI (currently known as Panasonic Corporation) to PHC IVD
- 1991
- Commenced production and sales of the first generation of glucose monitoring system for Japan market
- 1993
- Commenced sales of the first generation of glucose monitoring system for outside of Japan
- 1995
- Launched LPIA S500
- 2001
- Launched LPIA NV7
- 2003
-
- Commenced production and sales of the second generation of glucose monitoring system
- Started business directly with Bayer Corporation (currently known as Ascensia Diabetes Care)
- 2005
-
Commenced production and sales of lancet and lancet device
Launched PATHFAST
- 2006
- Commenced production and sales of motorized digital injector for growth hormone
- 2007
- Launched STACIA
- 2011
-
- Commenced operation of new factory plant for glucose sensors
- Commenced production and sales of the third generation of glucose monitoring system
PATHFAST cTnI received FDA approval and launched in the United States
- 2012
-
- Commenced production and sales of Point Of Care Testing System
- Commenced production and sales of blood glucose monitoring systems for hospitals and clinics
- Commenced production and sales of motorized digital injector for apomorphine hydrochloride
- 2013
-
Commenced production and sales of Fractional Nitric Oxide level measuring system
PATHFAST Presepsin approved by the Ministry of Health, Labour and Welfare in Japan
- 2015
- Acquisition of diabetes care business from Bayer AG to establish “Ascensia Diabetes Care”
- 2019
- Launched STACIA CN10
- 2020
- Launched growth hormone therapy medication management app
- 2021
- Commenced production and sales of motorized digital injector for rheumatoid arthritis
- 2023
-
- Commenced production and sales of motorized digital injector for osteogenesis promoter
- Integration of LSIM’s Diagnostic Reagents & Instruments business under PHC IVD